Hormonal

Rosiglitazone, a thiazolidinedione that increases insulin sensitivity by activating PPAR-gamma, delays monotherapy failure and preserves beta-cell function more effectively than metformin or glyburide in patients with recently diagnosed type 2 diabetes.

For newly diagnosed type 2 diabetics, rosiglitazone (8mg/day) may offer better long-term preservation of the pancreas's ability to produce insulin compared to metformin or glyburide, potentially delaying the need for additional medications. This benefit comes with the trade-off of potential side effects like weight gain or fluid retention, which should be monitored.